The combination of PL1-OX40 (ψ) + anti-OX40 with anti-PD-1 + anti-CTLA-4 Ab treatment dramatically inhibited tumor growth and prolonged survival in comparison to treatment with PBS or anti-PD-1 + anti-CTLA-4 Ab (Fig. 4g–i). This evidence concerns the gene TNFRSF4 and neoplasm.